Similar Articles
1131 Targeting the insulin-like growth factor pathway in hepatocellular carcinoma
1132 Recent advances in the surgical treatment of hepatocellular carcinoma
1133 Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma
1134 Interventional treatment for unresectable hepatocellular carcinoma
1135 Revisiting the role of pathological analysis in transarterial chemoembolization-treated hepatocellular carcinoma after transplantation
1136 Novel approach to identifying the hepatitis B virus pre-S deletions associated with hepatocellular carcinoma
1137 Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors
1138 Living-donor vs deceased-donor liver transplantation for patients with hepatocellular carcinoma
1139 Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection
1140 Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA